Search results
Expert Insights from ERA 2025
Video Series
Added:
6 days ago
ERA 2025 - Dr Ruben Nogueiras (University of Santiago de Compostela, Santiago, ES) joins us to discuss upcoming treatments that will soon be approved for the treatment of obesity, including dual agonists that will also target type two diabetes. As well as exploring the evolution of our understanding and classification of obesity, Dr Nogueiras shares his view of obesity a multifactorial disease…
View more
Added:
1 week ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of…
View more
Added:
1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
Added:
2 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical…
View more
Added:
1 month ago
Added:
1 year ago
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035).This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients…
View more
Added:
2 months ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,…
View more
Added:
2 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global…
View more
Added:
1 year ago
EHRA 24 - In this short interview, we are joined by Dr Laurent Fiorina (Cardiovascular Institute Paris-Sud (ICPS), FR) joins us to discuss the findings from a clinical investigation into diagnosing conduction tissue disease using an AI-enabled single-lead coronary ECG device.This observational, prospective clinical trial aims to investigate the performance of an artificial intelligence algorithm…
View more
